Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children

David M Burger; Alina S Bergshoeff; Ronald De Groot; Diana Gibb; Sarah Walker; Jean-Marc Tréluyer; Richard M W Hoetelmans; PENTA 5 study group

doi:10.1016/j.jpeds.2004.04.048

Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children

J Pediatr. 2004 Sep;145(3):403-5. doi: 10.1016/j.jpeds.2004.04.048.

Authors

David M Burger¹, Alina S Bergshoeff, Ronald De Groot, Diana Gibb, Sarah Walker, Jean-Marc Tréluyer, Richard M W Hoetelmans; PENTA 5 study group

Affiliation

¹ University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands. [email protected]

PMID: 15343199
DOI: 10.1016/j.jpeds.2004.04.048

Abstract

Differences in virologic response were compared in 32 HIV-infected children with a nelfinavir trough concentration either below (n=7) or above (n=25) 0.8 mg/L. Virologic response at week 48 was observed in 29% of children with subtherapeutic nelfinavir troughs versus 80% in children with therapeutic nelfinavir troughs (P=.02).

MeSH terms

Child
Child, Preschool
Drug Administration Schedule
Female
HIV Infections / blood*
HIV Infections / drug therapy
HIV Protease Inhibitors / blood
HIV Protease Inhibitors / pharmacokinetics*
HIV Protease Inhibitors / therapeutic use
Humans
Male
Nelfinavir / blood
Nelfinavir / pharmacokinetics*
Nelfinavir / therapeutic use

Substances

HIV Protease Inhibitors
Nelfinavir